HK1161976A1 - Method for inhibiting metastasis in a stem cell fusion model of carcinogenesis - Google Patents

Method for inhibiting metastasis in a stem cell fusion model of carcinogenesis

Info

Publication number
HK1161976A1
HK1161976A1 HK12102292.7A HK12102292A HK1161976A1 HK 1161976 A1 HK1161976 A1 HK 1161976A1 HK 12102292 A HK12102292 A HK 12102292A HK 1161976 A1 HK1161976 A1 HK 1161976A1
Authority
HK
Hong Kong
Prior art keywords
carcinogenesis
stem cell
cell fusion
fusion model
inhibiting metastasis
Prior art date
Application number
HK12102292.7A
Other languages
English (en)
Chinese (zh)
Inventor
David T Harris
Tom C Tsang
Xianghui He
Brian L Pipes
Linda C Meade-Tollin
Original Assignee
Univ Arizona State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State filed Critical Univ Arizona State
Publication of HK1161976A1 publication Critical patent/HK1161976A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12102292.7A 2005-08-25 2012-03-07 Method for inhibiting metastasis in a stem cell fusion model of carcinogenesis HK1161976A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71124905P 2005-08-25 2005-08-25

Publications (1)

Publication Number Publication Date
HK1161976A1 true HK1161976A1 (en) 2012-08-17

Family

ID=37772481

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102292.7A HK1161976A1 (en) 2005-08-25 2012-03-07 Method for inhibiting metastasis in a stem cell fusion model of carcinogenesis

Country Status (16)

Country Link
US (2) US8158126B2 (xx)
EP (2) EP2363146B1 (xx)
JP (2) JP5400381B2 (xx)
KR (2) KR101413055B1 (xx)
CN (2) CN103212071B (xx)
AU (2) AU2006282853B2 (xx)
BR (1) BRPI0615081A2 (xx)
CA (2) CA2620616C (xx)
ES (2) ES2523857T3 (xx)
HK (1) HK1161976A1 (xx)
HU (1) HUE025948T2 (xx)
IL (2) IL189674A (xx)
RU (1) RU2404805C2 (xx)
SG (1) SG152229A1 (xx)
WO (1) WO2007025216A2 (xx)
ZA (1) ZA200802512B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
EP2363146B1 (en) * 2005-08-25 2015-06-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for inhibiting metastasis in a stem cell fusion model of carcinogenesis
US20120295344A1 (en) * 2006-08-25 2012-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem Cell Fusion Model of Carcinogenesis
RU2507196C2 (ru) 2005-09-19 2014-02-20 Эмисфире Текнолоджис, Инк. Кристаллические формы динатриевой соли n-(5-хлорсалицилоил)-8-аминокаприловой кислоты
EP3309170B1 (en) 2005-12-15 2019-05-22 Genentech, Inc. Polyubiquitin antibodies
US8133488B2 (en) 2008-01-18 2012-03-13 Genentech, Inc. Methods and compositions for targeting polyubiquitin
CN101760452B (zh) * 2008-11-18 2012-12-19 中国科学院上海生命科学研究院 一种胚胎干细胞和肿瘤细胞的杂合细胞系及其构建方法
US8178307B2 (en) * 2009-09-02 2012-05-15 National Tsing Hua University Methods and compositions for detection of lethal cell and uses thereof
CA2793503A1 (en) 2010-04-15 2011-10-20 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
WO2012075679A1 (en) 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
KR20140054177A (ko) 2011-08-05 2014-05-08 제넨테크, 인크. 항-폴리유비퀴틴 항체 및 이용 방법
CN110391025A (zh) * 2018-04-19 2019-10-29 清华大学 一种面向宏微观多维度胃癌早期风险评估的人工智能建模方法
US11052041B1 (en) 2020-10-01 2021-07-06 King Abdulaziz University Nanotechnology-based nostril drops for relief of respiratory ailments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007321A2 (en) 1988-12-23 1990-07-12 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte receptor homing sequences and their uses
US6007816A (en) 1989-03-17 1999-12-28 Fred Hutchinson Cancer Research Center Methods of using CD44-specific antibodies
WO1994021294A1 (en) * 1993-03-19 1994-09-29 Bigner Darell D Method of treating tumors with antibodies
WO1997014306A1 (en) 1995-10-17 1997-04-24 Dovetail Technologies, Inc. Low molecular weight cell, bone marrow and immune stimulants
JP2004507459A (ja) * 1999-08-25 2004-03-11 アルタレックス　コーポレイション 免疫病態治療用組成物および方法
WO2004093646A2 (en) * 2003-04-18 2004-11-04 University Of Massachusetts Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer
CN1302102C (zh) * 2003-12-29 2007-02-28 中国医学科学院血液学研究所 通过扩增巨核祖细胞和成熟巨核细胞制备巨核细胞制剂的方法及用途
US20060033366A1 (en) 2004-08-11 2006-02-16 Jeffrey Vernon M Headrest display device
AU2006272780A1 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of California Heparin compostions and selectin inhibition
EP2363146B1 (en) * 2005-08-25 2015-06-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for inhibiting metastasis in a stem cell fusion model of carcinogenesis

Also Published As

Publication number Publication date
CA2808168A1 (en) 2007-03-01
JP2011225613A (ja) 2011-11-10
RU2404805C2 (ru) 2010-11-27
ES2523857T3 (es) 2014-12-02
CN103212071A (zh) 2013-07-24
CA2620616A1 (en) 2007-03-01
AU2006282853B2 (en) 2011-01-20
JP5597171B2 (ja) 2014-10-01
AU2011201605A1 (en) 2011-04-28
EP1924685A2 (en) 2008-05-28
IL189674A (en) 2012-10-31
EP2363146A1 (en) 2011-09-07
CN101273124A (zh) 2008-09-24
AU2006282853A1 (en) 2007-03-01
US8758755B2 (en) 2014-06-24
EP1924685B1 (en) 2014-08-27
US8158126B2 (en) 2012-04-17
JP2009505664A (ja) 2009-02-12
ZA200802512B (en) 2009-01-28
CN103212071B (zh) 2017-12-12
KR20080048499A (ko) 2008-06-02
HUE025948T2 (en) 2016-05-30
ES2552101T3 (es) 2015-11-25
EP1924685A4 (en) 2009-03-04
WO2007025216A2 (en) 2007-03-01
JP5400381B2 (ja) 2014-01-29
US20090016961A1 (en) 2009-01-15
EP2363146B1 (en) 2015-06-24
CN101273124B (zh) 2013-05-08
IL189674A0 (en) 2008-06-05
AU2011201605B2 (en) 2012-12-20
US20120201808A1 (en) 2012-08-09
CA2620616C (en) 2016-06-14
RU2008111144A (ru) 2009-09-27
CA2808168C (en) 2018-06-12
IL222468A (en) 2015-10-29
KR20130020738A (ko) 2013-02-27
KR101413055B1 (ko) 2014-07-02
SG152229A1 (en) 2009-05-29
WO2007025216A3 (en) 2007-07-05
KR101413048B1 (ko) 2014-06-30
BRPI0615081A2 (pt) 2011-05-03

Similar Documents

Publication Publication Date Title
HK1161976A1 (en) Method for inhibiting metastasis in a stem cell fusion model of carcinogenesis
HK1259231A1 (zh) 培養幹細胞的培養基
GB0601319D0 (en) A method of fabricating pillars composed of silicon-based material
GB0612406D0 (en) A method of making cell growth surface
GB2446525B (en) Stem cell culture medium and method
ZA200809978B (en) Method for selection of transformed cells
EP1875365A4 (en) GLOBAL MODEL FOR VPLS
HK1141251A1 (en) A method for enhancing cell response
PT2733203T (pt) Métodos de expansão de células estminais embrionárias numa cultura de suspensão
EP1924146A4 (en) METHOD FOR CELLULAR IMPLANTATION
EP2054079A4 (en) COMPOSITIONS FOR THE PROGRAMMING OF A CELL AND APPLICATIONS THEREOF
EP1891437A4 (en) METHOD FOR PROFILING A CELLULAR POPULATION
ZA200901914B (en) Stem cell culture medium and method
EP2007411A4 (en) REGULATORY STEM CELLS
EP2019479A4 (en) ONTABLE POWER SUPPLY AND METHOD FOR PROVIDING A POWER SUPPLY
EP2044197A4 (en) METHOD FOR PRODUCING A CELL POPULATION
EP1984117A4 (en) METHOD FOR CONTROLLING A BREAKER AND BREAKER
GB2433145B (en) Methods and systems for predictive modeling using a committee of models
GB2427173B (en) Method for use in controlling the buoyancy of a structure
PL1788077T3 (pl) Sposób tworzenia klastrów komórek
ZA200901945B (en) Hydrogen production method
GB0519848D0 (en) A method of trading
GB2425684B (en) A method of controlling noise rise in a cell
HK1154292A1 (en) Watch comprising a middle machined in a block of extra-hard material
PL1935797T3 (pl) Worek z zaworem i sposób jego wytwarzania

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190823